Authors
Latest:
Advent International, Warburg Pincus Complete $4.25 Billion Acquisition of Baxter’s BioPharma Solutions BusinessThe newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.
Latest:
Study Highlights PBMs’ Role in Drug PricesAn analysis by 3 Axis Advisors has found that there is a large variability in pharmacy reimbursement of prescription drugs depending on PBM contracts with insurers. This creates a system with huge inconsistencies on the prices of both generics and branded products.
Latest:
Pharma Pulse 4/26/24: Amazon Introduces Custom AI Capabilities, Crafting Culturally Sensitive Messages to Reach Diverse Audience & moreThe latest news for pharma industry insiders.
Latest:
Mark Cuban’s Cost Plus Drugs Partners with Price.comThe two company’s will provide consumers with a platform where they can compare drug prices.
Latest:
Continued Affordability Challenges in the OffingWill result from Medicare reforms, despite increased drug uptake.
Latest:
Raising the stakes for market access supportCase study on closing the gap between new specialty drugs and specialty pharmacies
Latest:
How to Maximize Pharmacy Reimbursement for Every Order and Prevent Costly Write-OffsQuestions pharmacies should ask when choosing the right proof-of-delivery solution
Latest:
Beyond Payment MethodsThe need for supporting services in copay accumulator and best price areas
Latest:
The Importance of Having the Biopharma Industry Join the Journey to Net-Zero EmissionsHow setting action-based goals and cultivating partnerships will help overcome challenges associated with implementing a sustainable GHG strategy.
Latest:
Democratizing AI: Bridging the Intelligence Divide in Commercial Life SciencesSmall and emerging biopharma have been historically reserved about artificial intelligence. But, writes Alan Kalton, AI solutions have matured, been proven, and are no longer a risky investment for small to mid-size companies.
Latest:
Realistic Net-Zero Goals for PharmaHow temperature-controlled containers can play key role in the industry's mission for carbon neutrality across the supply chain.
Latest:
What Will Change in the Pharma Industry Look Like?Exploring how current and future legislation may impact the role of pharmacy benefit managers (PBMs).
Latest:
What Health & Wellness Companies Need to Know About the New Provider/Patient RelationshipHow has the provider-patient relationship transformed over the past two years, and what care are consumers craving?
Latest:
Pharma's Journey with Patient Family Advisory CouncilsIncluding patient and family feedback in our discussions will help shape our understanding of their perception of provided care and services and how we operate as a whole.
Latest:
Creating Value from Compliance DataHow maximizing the intelligence gained from brand engagement compliance activities can help drive pharmaceutical company commercial decisions.
Latest:
Streamlining for Safety: Navigating Changes and Trends in the Pharmaceutical Supply Chain Post-DSCSAWith its aims to protect healthcare consumers against the dangers of counterfeit, contaminated, stolen or otherwise harmful drugs, the DSCSA represents a significant step forward in securing the pharmaceutical supply chain.
Latest:
Climbing Health Care Costs Result in Elevated Employer VigilanceSoaring healthcare costs show little sign of abating in 2024, and concerns about the affordability of medications and medical services continue to grow, despite investments in technology, clinical innovation, and efforts to manage utilization and waste.
Latest:
Preparing for the Growth of Cold ChainCardinal Health helps create a more predictable and efficient supply chain by investing in the future of cold-chain storage and transportation.
Latest:
The Future State of Oncology: The Rise of Oncology Home CareWhile there are still hurdles to overcome along the way, home healthcare could deliver better patient-centered cancer care, providing improved patient outcomes, enhanced quality of life, and reduced strain on resources.
Latest:
What Do Pharmaceutical Manufacturers Actually Want Most from a Hub?Among a variety of Hub vendors, what specific qualities distinguish differentiated support for drug manufacturers? To help answer this question, CareMetx conducted in-depth interviews and surveys with senior leadership at top manufacturers.
Latest:
New Serialization Mandates Inch CloserPressure is mounting ahead of looming unit-level serialization required by the Drug Supply Chain Security Act—necessitating a wide scope of collaboration on compliance
Latest:
Evaluating Patient Support Programs: Opportunities and PitfallsAssessing the efficacy of patient support programs is the first step to optimizing their resource allocation and program design for maximized patient benefit.
Latest:
Key Supply Chain Tech Trends for 2023Outlining those advances poised to drive increased use of integrated tactical planning (ITP) in helping manufacturers overcome persistent supply chain obstacles.
Latest:
FDA Issues Complete Response Letter to Abeona Therapeutics Regarding PZ-Cel for Recessive Dystrophic Epidermolysis BullosaCiting a need for more Chemistry Manufacturing and Controls information, Abeona intends to address the requirements quickly.
Latest:
A Game Changer for Commercial Insights?Configuration-driven SaaS, powered by modern data management technology, can enable orphan drug manufacturers to form effective commercial strategies
Latest:
Specialty access barriers: How technology can help2020 was a difficult year for many patients, but new data may signal a brighter future ahead
Latest:
How Healthcare Economics Outcomes Evidence Can Pave the Way for Digital TherapeuticsIn the face of chronic disease, DTx have the opportunity to provide a lifeline to patients.
Latest:
Exclusivity Creates Challenges in Price, Access for Long-used MedicationsFDA’s Unapproved Drug Initiative (UDI) is a well-intentioned program in its encouragement of formal FDA review for unapproved legacy medications. But it has inadvertently created financial challenges and access issues, write Steven Lucio and Jenna Stern
